Pharmacological characterization of morphine-6 beta-glucuronide, a very potent morphine metabolite

D Paul, KM Standifer, CE Inturrisi and GW Pasternak

Cotzias Laboratory of Neuro-Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York.

Morphine-6 beta-glucuronide is a major metabolite of morphine with potent analgesic actions. To define more fully the importance of this compound in morphine action, we have compared the analgesic actions of morphine and its 6 beta-glucuronide metabolite after both peripheral and central administration. Given s.c., morphine-6 beta-glucuronide elicited analgesia with an effect approximately twice that of morphine due, in part, to its long duration of action and also inhibited gastrointestinal motility. Both actions were easily reversed by naloxone (s.c.). However, when injected either i.c.v. or intrathecally, morphine-6 beta-glucuronide was approximately 90- and 650-fold more potent an analgesic than morphine, respectively. Whereas morphine in these studies was equipotent at both levels of the neuraxis as an analgesic, the 6 beta-glucuronide was approximately 5-fold more effective at the level of the spinal cord than supraspinally. The mu 1- selective antagonist naloxonazine blocked the analgesic effect of systemic and i.c.v. morphine-6 beta-glucuronide much as it blocked morphine, implying a role for mu1 receptors in these actions. Like morphine, morphine-6 beta-glucuronide analgesia after intrathecal injection was not sensitive to naloxonazine, suggesting a mu2 mechanism within the spinal cord. Together, these results imply that morphine-6 beta-glucuronide elicited its analgesic actions through the same receptor mechanisms as morphine. Mice highly tolerant to morphine after implantation of morphine pellets showed cross-tolerance to morphine-6 beta-glucuronide (s.c.). The high potency of morphine-6 beta- glucuronide strongly suggests that this metabolite plays an important role in morphine's actions.

Volume 251, Issue 2, pp. 477-483, 11/01/1989
Copyright © 1989 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				J. Temsamani, C. Bonnafous, C. Rousselle, Y. Fraisse, P. Clair, L.-A. Granier, A. R. Rees, M. Kaczorek, and J.-M. Scherrmann Improved Brain Uptake and Pharmacological Activity Profile of Morphine-6-Glucuronide Using a Peptide Vector-Mediated Strategy J. Pharmacol. Exp. Ther., May 1, 2005; 313(2): 712 - 719. [Abstract] [Full Text] [PDF]

				R. D. Knaggs, I. M. Crighton, T. F. Cobby, A. J. P. Fletcher, and G. J. Hobbs The Pupillary Effects of Intravenous Morphine, Codeine, and Tramadol in Volunteers Anesth. Analg., July 1, 2004; 99(1): 108 - 112. [Abstract] [Full Text] [PDF]

				P. Klepstad, P. C Borchgrevink, O. Dale, K. Zahlsen, T. Aamo, P. Fayers, B. Fougner, and S. Kaasa Routine drug monitoring of serum concentrations of morphine, morphine-3-glucuronide and morphine-6-glucuronide do not predict clinical observations in cancer patients Palliative Medicine, December 1, 2003; 17(8): 679 - 687. [Abstract] [PDF]

				N. A. Rasmussen and L. A. Farr Effects of Morphine and Time of Day on Pain and Beta-Endorphin Biol Res Nurs, October 1, 2003; 5(2): 105 - 116. [Abstract] [PDF]

				I. Tegeder, S. Meier, M. Burian, H. Schmidt, G. Geisslinger, and J. Lotsch Peripheral opioid analgesia in experimental human pain models Brain, May 1, 2003; 126(5): 1092 - 1102. [Abstract] [Full Text] [PDF]

				M. K. Shelby, N. J. Cherrington, N. R. Vansell, and C. D. Klaassen Tissue mRNA Expression of the Rat UDP-Glucuronosyltransferase Gene Family Drug Metab. Dispos., March 1, 2003; 31(3): 326 - 333. [Abstract] [Full Text] [PDF]

				T. D. Moran and P. A. Smith Morphine-3beta -D-glucuronide Suppresses Inhibitory Synaptic Transmission in Rat Substantia Gelatinosa J. Pharmacol. Exp. Ther., August 1, 2002; 302(2): 568 - 576. [Abstract] [Full Text] [PDF]

				C. A. Bowen, B. D. Fischer, N. K. Mello, and S. S. Negus Antagonism of the Antinociceptive and Discriminative Stimulus Effects of Heroin and Morphine by 3-Methoxynaltrexone and Naltrexone in Rhesus Monkeys J. Pharmacol. Exp. Ther., July 1, 2002; 302(1): 264 - 273. [Abstract] [Full Text] [PDF]

				J. Mei and G. W. Pasternak sigma 1 Receptor Modulation of Opioid Analgesia in the Mouse J. Pharmacol. Exp. Ther., March 1, 2002; 300(3): 1070 - 1074. [Abstract] [Full Text] [PDF]

				M. T. Smith, A. W. E. Wright, B. E. Williams, G. Stuart, and T. Cramond Cerebrospinal Fluid and Plasma Concentrations of Morphine, Morphine-3-Glucuronide, and Morphine-6-Glucuronide in Patients Before and After Initiation of Intracerebroventricular Morphine for Cancer Pain Management Anesth. Analg., January 1, 1999; 88(1): 109 - 116. [Abstract] [Full Text] [PDF]

				L. Leventhal, R. M. Silva, G. C. Rossi, G. W. Pasternak, and R. J. Bodnar Morphine-6beta -Glucuronide-Induced Hyperphagia: Characterization of Opioid Action By Selective Antagonists and Antisense Mapping in Rats J. Pharmacol. Exp. Ther., November 1, 1998; 287(2): 538 - 544. [Abstract] [Full Text]

				S. M. South and M. T. Smith Apparent Insensitivity of the Hotplate Latency Test for Detection of Antinociception Following Intraperitoneal, Intravenous or Intracerebroventricular M6G Administration to Rats J. Pharmacol. Exp. Ther., September 1, 1998; 286(3): 1326 - 1332. [Abstract] [Full Text]

				I. E. Goldberg, G. C. Rossi, S. R. Letchworth, J. P. Mathis, J. Ryan-Moro, L. Leventhal, W. Su, D. Emmel, E. A. Bolan, and G. W. Pasternak Pharmacological characterization of Endomorphin-1 and Endomorphin-2 in Mouse Brain J. Pharmacol. Exp. Ther., August 1, 1998; 286(2): 1007 - 1013. [Abstract] [Full Text]

				T. A Aasmundstad and P. Storset Influence of ranitidine on the morphine-3- glucuronide to morphine-6-glucuronide ratio after oral administration of morphine in humans Human and Experimental Toxicology, June 1, 1998; 17(6): 347 - 352. [Abstract] [PDF]

				F. Stain-Texier, P. Sandouk, and J-M. Scherrmann Intestinal Absorption and Stability of Morphine 6-Glucuronide in Different Physiological Compartments of the Rat Drug Metab. Dispos., May 1, 1998; 26(5): 383 - 387. [Abstract] [Full Text]

				J. W. Lohr, G. R. Willsky, and M. A. Acara Renal Drug Metabolism Pharmacol. Rev., March 1, 1998; 50(1): 107 - 142. [Abstract] [Full Text] [PDF]

				J. H. Lin and A. Y. H. Lu Role of Pharmacokinetics and Metabolism in Drug Discovery and Development Pharmacol. Rev., December 1, 1997; 49(4): 403 - 449. [Abstract] [Full Text] [PDF]

				G. P. Brown, K. Yang, O. Ouerfelli, K. M. Standifer, D. Byrd, and G. W. Pasternak 3H-Morphine-6beta -Glucuronide Binding in Brain Membranes and an MOR-1-Transfected Cell Line J. Pharmacol. Exp. Ther., September 1, 1997; 282(3): 1291 - 1297. [Abstract] [Full Text]

				L. Leventhal, L. B. Stevens, G. C. Rossi, G. W. Pasternak, and R. J. Bodnar Antisense Mapping of the MOR-1 Opioid Receptor Clone: Modulation of Hyperphagia Induced by DAMGO J. Pharmacol. Exp. Ther., September 1, 1997; 282(3): 1402 - 1407. [Abstract] [Full Text]

				D. Wu, Y.-S. Kang, U. Bickel, and W. M. Pardridge Blood-Brain Barrier Permeability to Morphine-6-Glucuronide is Markedly Reduced Compared with Morphine Drug Metab. Dispos., June 1, 1997; 25(6): 768 - 771. [Abstract] [Full Text]

				G. C. Rossi, L. Leventhal, Y.-X. Pan, J. Cole, W. Su, R. J. Bodnar, and G. W. Pasternak Antisense Mapping of MOR-1 in Rats: Distinguishing between Morphine and Morphine-6beta -glucuronide Antinociception J. Pharmacol. Exp. Ther., April 1, 1997; 281(1): 109 - 114. [Abstract] [Full Text]